Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Corbus Pharmaceuticals Inc.
An interventional, double-blind, randomized, placebo-control design will be used to test safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in 70 subjects ≥ 18 and \< 65 years of age with documented cystic fibrosis. There will up a screening period of up to 28 days, 84 days treatment period, and 28 days follow-up.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documentation of a CF diagnosis as evidenced by 1 or more clinical features consistent with the CF phenotype and 1 or more of the following criteria:
1. Sweat chloride equal to or greater than 60 mEq/L by quantitative pilocarpine iontophoresis test;
2. Two well-characterized mutations in the CFTR gene
FEV1 ≥ 40% predicted corrected
Stable treatment of CF for 14 days before Visit 1
You may not be if
Severe or unstable CF, such as:
1. Intravenous antibiotic treatment within 14 days before Visit 1
2. Treatment with any corticosteroids \> 10 mg per day or \> 20 mg every other day oral prednisone or equivalent within 14 days before Visit 1
Any one of the following values for laboratory tests at Screening:
1. A positive pregnancy test (or at Visit 1);
2. Hemoglobin \< 10 g/dL
3. Neutrophils \< 1.0 x 10\~9/L
4. Platelets \< 75 x 10\~9/L
5. Creatinine clearance \< 50 ml/min according to modified Cockcroft-Gault equation
6. Serum transaminases \> 2.5 x upper normal limit
7. Total bilirubin ≥ 1.5 x upper limit of normal
Any other condition that, in the opinion of the Principal Investigator, is clinically significant and may put the subject at greater safety risk, influence response to study product, or interfere with study assessments.